[The antiviral activity of inhibitors of ADP ribosylation in experimental alpha- and bunyavirus infections].
The prophylactic and therapeutic effects of ADP-ribosylation inhibitors, 3,N-acetylaminobenzamide and 3,N-butyrylaminobenzamide, were studied in mice inoculated with an alphavirus or a bunyavirus. Both drugs were shown to have high levels of antiviral activity when given as a single subcutaneous injection in a dose of 10 mg/kg while increasing the number of injections did not increase their efficacy or might even decrease it.
I I
II
Krasil'nikov
E V
EV
Levshina
R I
RI
Belova
V V
VV
Starenchenko
G V
GV
Tsikarishvili
V V
VV
Katsalukha
D000246:Adenosine Diphosphate Ribose / Q000037:antagonists & inhibitors*; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004663:Encephalitis Virus, Eastern Equine; D004683:Encephalomyelitis, Equine / Q000188:drug therapy* / Q000401:mortality; D004685:Encephalomyelitis, Venezuelan Equine / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D012254:Ribavirin / Q000627:therapeutic use; D012295:Rift Valley Fever / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors
D000998:Antiviral Agents; D001549:Benzamides; C088105:3-(N-butyrylamino)benzamide; D000246:Adenosine Diphosphate Ribose; D012254:Ribavirin; C040561:3-acetamidobenzamide
Protivovirusnaia aktivnost' nekotorykh ingibitorov ADF-ribozilirovaniia pri éksperimental'nykh al'fa- i bun'iavirusnykh infektsiiakh.